Skip to main content
UniHealth

Doctor search

Joel W Neal, MD

Medical Oncology · Stanford

NPI 1790858942

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Neal’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
Anthem Full Dual Advantage Aligned (HMO D-SNP)Anthem Blue CrossListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026

California Medical Board record

Licence A111199 · Current

Licensed to practise in California · since 2010 · expires 2027-08-31 · Northwestern University Medical School.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$114,410

Medicare paid this office $114,410 for 248 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)96$35,920$170
Long return visit (40+ min)95$34,958$127
Return visit (30+ min)73$13,363$121
Return visit (30+ min)77$9,376$82
New patient visit (60+ min)35$5,443$156
See all 8 services
Every Original Medicare service billed
Long return visit (40+ min)96$35,920$170
Long return visit (40+ min)95$34,958$127
Return visit (30+ min)73$13,363$121
Return visit (30+ min)77$9,376$82
New patient visit (60+ min)35$5,443$156
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's109$3,670$15
New patient visit (60+ min)15$2,930$195
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's92$2,651$15

Who their Medicare patients are

248 Original Medicare patients in 2024. Average age 74 · Under 65 7% · 85 and older 12% · Women 56% · Also on Medicaid 22% · Health risk score 2.64. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: Cancer 75% · High blood pressure 67% · Coronary heart disease 27% · Chronic kidney disease 27% · COPD 25% · Diabetes 24% · Atrial fibrillation 22% · Heart failure 16% · Depression 14% · Stroke 14%.

The office billed $444,055, Medicare allowed $146,738 and paid $114,410; for 1,246 services of 13 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20242481,246742.64$444,055$114,410
2023256906752.49$415,653$107,696
2022244848752.53$377,174$103,624
2021234834742.56$380,688$98,570
2020211912742.56$329,637$82,616
2019246995742.71$171,689$90,171
2018238923722.61$151,762$84,201
2017224837722.41$198,700$76,391
2016235800722.47$224,635$73,242
2015221823722.47$229,341$74,703
20142421,003722.16$260,692$86,792
2013179793722.13$200,039$65,025

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 8 services

Original Medicare services billed in 2023
Long return visit (40+ min)158$69,816$130
Return visit (30+ min)123$17,124$87
New patient visit (60+ min)53$8,818$166
Initial hospital care with moderate level of medical decision making at least 75 minutes23$3,836$160
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes14$2,852$110
Hospital discharge day management, more than 30 minutes16$1,712$107
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes11$1,532$73
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes11$768$45

2022: 6 services

Original Medicare services billed in 2022
Long return visit (40+ min)165$70,465$130
Return visit (30+ min)83$11,776$89
New patient visit (60+ min)52$8,789$169
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes25$6,558$94
Initial hospital care with moderate level of medical decision making at least 75 minutes13$2,400$185
Hospital discharge day management, more than 30 minutes12$1,179$98

2021: 5 services

Original Medicare services billed in 2021
Long return visit (40+ min)151$60,964$129
Return visit (30+ min)115$18,066$87
New patient visit (60+ min)49$8,403$171
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes15$3,723$95
Initial hospital care with moderate level of medical decision making at least 75 minutes11$1,997$182

2020: 8 services

Original Medicare services billed in 2020
Long return visit (40+ min)121$31,069$103
Return visit (30+ min)139$26,995$69
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes20$7,947$98
New patient visit (60+ min)39$6,050$155
Initial hospital care with moderate level of medical decision making at least 75 minutes13$2,793$200
Return visit (30+ min)27$2,263$75
Long return visit (40+ min)13$1,821$121
Hospital discharge day management, more than 30 minutes11$1,149$104

2019: 7 services

Original Medicare services billed in 2019
Long return visit (40+ min)137$36,031$97
Return visit (30+ min)124$25,627$69
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes32$9,150$94
New patient visit (60+ min)57$8,240$145
Initial hospital care with moderate level of medical decision making at least 75 minutes25$4,772$184
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes17$1,782$66
Hospital discharge day management, more than 30 minutes12$1,190$99

2018: 6 services

Original Medicare services billed in 2018
Long return visit (40+ min)138$38,369$99
Return visit (30+ min)112$22,622$67
New patient visit (60+ min)61$9,038$148
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes20$4,775$94
Initial hospital care with moderate level of medical decision making at least 75 minutes23$4,366$182
Hospital discharge day management, more than 30 minutes13$1,284$99

2017: 6 services

Original Medicare services billed in 2017
Long return visit (40+ min)108$26,719$98
Return visit (30+ min)99$22,164$68
New patient visit (60+ min)77$11,455$149
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes33$7,976$93
Initial hospital care with moderate level of medical decision making at least 75 minutes18$3,263$181
Hospital discharge day management, 30 minutes or less11$729$66

2016: 7 services

Original Medicare services billed in 2016
Long return visit (40+ min)107$22,068$99
Return visit (30+ min)101$21,905$69
New patient visit (60+ min)72$10,618$147
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes34$6,852$93
Initial hospital care with moderate level of medical decision making at least 75 minutes22$4,023$175
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes21$1,993$64
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes16$1,944$121

2015: 7 services

Original Medicare services billed in 2015
Return visit (30+ min)101$22,589$68
Long return visit (40+ min)101$22,319$99
New patient visit (60+ min)67$9,868$147
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes23$7,891$93
Initial hospital care with moderate level of medical decision making at least 75 minutes27$5,235$181
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes15$2,196$65
Hospital discharge day management, more than 30 minutes15$1,560$97

2014: 7 services

Original Medicare services billed in 2014
Return visit (30+ min)116$36,276$68
Long return visit (40+ min)91$17,491$95
New patient visit (60+ min)100$15,044$149
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes25$6,562$92
Initial hospital care with moderate level of medical decision making at least 75 minutes24$4,497$180
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes19$2,754$64
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes13$1,582$122

2013: 6 services

Original Medicare services billed in 2013
Return visit (30+ min)91$27,837$64
Long return visit (40+ min)77$13,790$94
New patient visit (60+ min)63$8,864$141
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes23$5,946$90
Initial hospital care with moderate level of medical decision making at least 75 minutes22$3,845$175
Hospital discharge day management, more than 30 minutes17$1,608$95

Medicaid work

$6,955 in 2024

Medicaid paid $6,955 for 84 billed services this clinician did in 2024, up to 17 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)70$6,311
Return visit (30+ min)14$645
Medicaid work by year
202484217$6,955
2023360326$15,040
2022121220$4,507
2021120415$6,732
2020101216$3,650
201991317$3,444
201812112$553
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)234$10,123
Return visit (30+ min)110$3,936
1ST HOSP IP/OBS HIGH 7516$980

2022

Largest Medicaid services in 2022
Long return visit (40+ min)78$2,914
Return visit (30+ min)43$1,593

2021

Largest Medicaid services in 2021
1ST HOSP IP/OBS HIGH 7516$2,022
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES29$2,022
Long return visit (40+ min)57$2,011
Return visit (30+ min)18$678

2020

Largest Medicaid services in 2020
Return visit (30+ min)66$2,478
Long return visit (40+ min)35$1,172

2019

Largest Medicaid services in 2019
Return visit (30+ min)66$2,230
1ST HOSP IP/OBS HIGH 7512$646
Long return visit (40+ min)13$568

2018

Largest Medicaid services in 2018
Long return visit (40+ min)12$553

Drugs they prescribed that Part D paid

$464,638

Pharmacies billed $464,638 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

92 generic and 31 brand-name prescriptions · $464,638 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Tagrisso24$390,412$16,267
Rosuvastatin11$666$61
Prochlorperazine Maleate12$90$8

Year by year

Part D prescribing by year
202412347None25%$464,638
202320057NoneNone$969,078
202214040None32%$650,124
20219338None40%$550,093
202024658None39%$1,052,682
2019332774% (12)43%$1,641,856
201839588None46%$2,120,653
201744086NoneNone$1,743,292
2016460863% (14)51%$1,770,084
2015447814% (17)None$771,406
2014513806% (31)None$477,395
2013543744% (21)None$186,768

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 1 drug

Part D drugs prescribed in 2023
Tagrisso37$621,684$16,802

2022: 1 drug

Part D drugs prescribed in 2022
Tagrisso20$336,048$16,802

2021: 1 drug

Part D drugs prescribed in 2021
Tagrisso24$412,504$17,188

2020: 8 drugs

Part D drugs prescribed in 2020
Tagrisso34$527,082$15,502
Xalkori12$224,304$18,692
Lorbrena11$179,702$16,337
Ondansetron16$276$17
Prochlorperazine Maleate20$275$14
Dexamethasone14$249$18
Levothyroxine11$200$18
Prednisone17$107$6

2019: 7 drugs

Part D drugs prescribed in 2019
Tagrisso81$1,253,782$15,479
Xalkori14$247,696$17,693
Dexamethasone18$303$17
Levothyroxine13$277$21
Prednisone24$186$8
Ondansetron17$178$10
Prochlorperazine Maleate16$174$11

2018: 9 drugs

Part D drugs prescribed in 2018
Tagrisso77$1,154,577$14,995
Tarceva35$274,877$7,854
Xalkori15$252,775$16,852
Alecensa14$201,366$14,383
Ondansetron20$256$13
Dexamethasone12$127$11
Lorazepam19$83$4
Prochlorperazine Maleate12$60$5
Omeprazole16$59$4

2017: 8 drugs

Part D drugs prescribed in 2017
Tarceva75$569,712$7,596
Xalkori33$519,803$15,752
Tagrisso29$404,586$13,951
Ondansetron34$794$23
Dexamethasone28$401$14
Prochlorperazine Maleate14$105$8
Ondansetron Odt11$94$9
Lorazepam28$78$3

2016: 10 drugs

Part D drugs prescribed in 2016
Tagrisso53$705,416$13,310
Tarceva96$651,077$6,782
Xalkori25$385,076$15,403
Entecavir11$10,331$939
Enoxaparin18$6,887$383
Clindamycin Phosphate11$837$76
Dexamethasone22$175$8
Ondansetron19$162$9
Prochlorperazine Maleate20$150$7
Lorazepam27$125$5

2015: 7 drugs

Part D drugs prescribed in 2015
Tarceva88$539,484$6,130
Xalkori12$159,329$13,277
Dexamethasone48$531$11
Ondansetron27$304$11
Prochlorperazine Maleate34$198$6
Gabapentin11$131$12
Lorazepam17$81$5

2014: 9 drugs

Part D drugs prescribed in 2014
Tarceva75$453,557$6,047
Clindamycin Phosphate18$1,292$72
Hydrocodone-Acetaminophen15$501$33
Ondansetron39$468$12
Dexamethasone39$317$8
Prochlorperazine Maleate38$224$6
Ondansetron Odt13$156$12
Lorazepam20$116$6
Citalopram Hbr16$68$4

2013: 15 drugs

Part D drugs prescribed in 2013
Tarceva26$136,531$5,251
Enoxaparin12$17,127$1,427
Advair Diskus11$2,849$259
Clindamycin Phosphate29$1,702$59
Combigan14$1,337$96
Nystatin16$797$50
Hydrocodone-Acetaminophen21$502$24
Megestrol Acetate11$392$36
Ondansetron23$373$16
Gabapentin11$292$27
Dexamethasone34$269$8
Prochlorperazine Maleate34$253$7
Lorazepam38$203$5
Anastrozole11$173$16
Zolpidem11$71$6

Money from drug and device companies

$37,752 in 2025

Industry payments by year
20251025$37,151$37,752
20241342$72,810$73,791
2023918$16,571$17,735
20221014$30,658$30,989
2021710$23,084$23,084
202033$11,174$11,174
201926$3,100$4,115

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Iovance BiotherapeuticsAmtagvi$10,875
3 payments
  • Consulting for Amtagvi · 2025-06-17 · $2,625
  • Consulting for Amtagvi · 2025-04-24 · $3,750
  • Consulting for Amtagvi · 2025-01-22 · $4,500
Taiho OncologyNone$5,984
4 payments
  • Consulting · 2025-11-12 · $390
  • Consulting · 2025-11-12 · $2,340
  • Consulting · 2025-07-01 · $3,120
  • Meals · 2025-05-30 · $134
Janssen BiotechRybrevant$5,810
8 payments
  • Consulting for Rybrevant · 2025-12-18 · $626
  • Consulting for Rybrevant · 2025-12-11 · $1,670
  • Consulting for Rybrevant · 2025-06-30 · $1,620
  • Meals for Rybrevant · 2025-05-29 · $94
  • Meals for Rybrevant · 2025-05-29 · $14
  • Meals for Rybrevant · 2025-04-01 · $15
  • Consulting for Rybrevant · 2025-03-13 · $1,620
  • Meals for Rybrevant · 2025-02-20 · $150
Janssen Scientific AffairsRybrevant$4,650
2 payments
  • Consulting for Rybrevant · 2025-11-03 · $2,325
  • Consulting for Rybrevant · 2025-04-16 · $2,325
AstraZeneca Pharmaceuticals LPTagrisso$3,005
2 payments
  • Consulting for Tagrisso · 2025-08-06 · $2,870
  • Meals for Datroway · 2025-06-01 · $135
Eli Lilly andNone$2,790
2 payments
  • Consulting · 2025-09-15 · $1,800
  • Consulting · 2025-06-23 · $990
See all 25 published payments
Every published payment
Janssen BiotechConsulting · 2025-12-18Rybrevant$626
Janssen BiotechConsulting · 2025-12-11Rybrevant$1,670
Taiho OncologyConsulting · 2025-11-12None$390
Taiho OncologyConsulting · 2025-11-12None$2,340
Janssen Scientific AffairsConsulting · 2025-11-03Rybrevant$2,325
Genentech USAConsulting · 2025-10-16Tecentriq$760
Eli Lilly andConsulting · 2025-09-15None$1,800
PfizerMeals · 2025-09-07Braftovi$58
AstraZeneca Pharmaceuticals LPConsulting · 2025-08-06Tagrisso$2,870
Taiho OncologyConsulting · 2025-07-01None$3,120
Janssen BiotechConsulting · 2025-06-30Rybrevant$1,620
Eli Lilly andConsulting · 2025-06-23None$990
Iovance BiotherapeuticsConsulting · 2025-06-17Amtagvi$2,625
AstraZeneca Pharmaceuticals LPMeals · 2025-06-01Datroway$135
Taiho OncologyMeals · 2025-05-30None$134
Janssen BiotechMeals · 2025-05-29Rybrevant$94
Janssen BiotechMeals · 2025-05-29Rybrevant$14
Iovance BiotherapeuticsConsulting · 2025-04-24Amtagvi$3,750
Janssen Scientific AffairsConsulting · 2025-04-16Rybrevant$2,325
Janssen BiotechMeals · 2025-04-01Rybrevant$15
Boehringer Ingelheim PharmaceuticalsConsulting · 2025-03-25None$2,220
Janssen BiotechConsulting · 2025-03-13Rybrevant$1,620
Janssen BiotechMeals · 2025-02-20Rybrevant$150
GlaxoSmithKlineConsulting · 2025-01-30None$1,600
Iovance BiotherapeuticsConsulting · 2025-01-22Amtagvi$4,500
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $73,791

Payments by company in 2024
Iovance BiotherapeuticsAmtagvi$13,875
9 payments
  • Consulting for Amtagvi · 2024-07-19 · $1,875
  • Consulting for Amtagvi · 2024-07-19 · $750
  • Consulting for Amtagvi · 2024-07-19 · $750
  • Consulting for Amtagvi · 2024-05-06 · $2,250
  • Consulting for Amtagvi · 2024-05-06 · $1,125
  • Consulting for Amtagvi · 2024-05-06 · $375
  • Consulting for Amtagvi · 2024-04-23 · $3,000
  • Consulting for Amtagvi · 2024-04-23 · $1,500
  • Consulting for Amtagvi · 2024-04-23 · $2,250
AmgenNplate$12,485
2 payments
  • Consulting for Nplate · 2024-11-05 · $7,749
  • Consulting for Nplate · 2024-03-07 · $4,736
AbbvieNone$11,269
4 payments
  • Consulting · 2024-12-13 · $4,050
  • Consulting · 2024-09-20 · $3,600
  • Meals · 2024-09-07 · $19
  • Consulting · 2024-06-06 · $3,600
AstraZeneca Pharmaceuticals LPEnhertu$10,094
9 payments
  • Consulting · 2024-12-13 · $2,460
  • Consulting · 2024-10-23 · $4,510
  • Meals · 2024-10-04 · $135
  • Meals for Tagrisso · 2024-02-21 · $22
  • Meals for Tagrisso · 2024-02-21 · $49
  • Meals for Tagrisso · 2024-02-21 · $80
  • Meals for Tagrisso · 2024-02-21 · $52
  • Meals for Tagrisso · 2024-02-21 · $45
  • Consulting for Enhertu · 2024-02-05 · $2,740
Janssen Scientific AffairsNone$7,800
5 payments
  • Consulting · 2024-09-24 · $2,325
  • Consulting · 2024-09-12 · $3,100
  • Meals · 2024-09-07 · $15
  • Meals · 2024-09-07 · $35
  • Consulting · 2024-05-15 · $2,325
Boehringer Ingelheim International GmbHNone$4,810
1 payment
  • Consulting · 2024-02-19 · $4,810
Eli Lilly andRetevmo$4,616
3 payments
  • Consulting for Retevmo · 2024-09-13 · $1,350
  • Consulting for Retevmo · 2024-09-13 · $3,150
  • Meals · 2024-09-08 · $116
Janssen BiotechRybrevant$2,965
3 payments
  • Consulting for Rybrevant · 2024-06-28 · $2,625
  • Meals for Rybrevant · 2024-05-31 · $65
  • Travel for Rybrevant · 2024-05-30 · $275
Gilead SciencesNone$2,870
1 payment
  • Consulting · 2024-07-22 · $2,870
GlaxoSmithKlineNone$1,600
1 payment
  • Consulting · 2024-11-15 · $1,600
Daiichi SankyoEnhertu$702
2 payments
  • Consulting · 2024-06-19 · $685
  • Meals for Enhertu · 2024-01-20 · $17
E.R. Squibb & Sons L.L.C.None$650
1 payment
  • Consulting · 2024-01-11 · $650
Genentech USAAlecensa$55
1 payment
  • Meals for Alecensa · 2024-01-20 · $55

2023: $17,735

Payments by company in 2023
Gilead SciencesTrodelvy$6,729
8 payments
  • Consulting · 2023-09-27 · $2,870
  • Meals for Trodelvy · 2023-09-10 · $59
  • Travel · 2023-04-04 · $99
  • Travel · 2023-04-04 · $406
  • Consulting · 2023-02-24 · $3,170
  • Meals · 2023-02-22 · $48
  • Meals · 2023-02-22 · $48
  • Meals · 2023-02-22 · $28
Novocure GmbHNone$4,770
1 payment
  • Honoraria · 2023-07-19 · $4,770
AbbvieNone$3,600
1 payment
  • Consulting · 2023-02-08 · $3,600
E.R. Squibb & Sons L.L.C.None$1,330
2 payments
  • Consulting · 2023-10-25 · $1,300
  • Meals · 2023-09-30 · $30
AmgenNplate$861
1 payment
  • Consulting for Nplate · 2023-02-20 · $861
NovocureNone$153
2 payments
  • Meals · 2023-04-20 · $7
  • Meals · 2023-03-29 · $147
Genentech USATecentriq$116
1 payment
  • Meals for Tecentriq · 2023-01-21 · $116
ExelixisNone$105
1 payment
  • Meals · 2023-03-30 · $105
AstraZeneca Pharmaceuticals LPNone$71
1 payment
  • Meals · 2023-09-10 · $71

2022: $30,989

Payments by company in 2022
AmgenNplate$7,672
3 payments
  • Consulting for Nplate · 2022-12-06 · $2,700
  • Consulting for Nplate · 2022-06-14 · $4,950
  • Meals for Lumakras · 2022-02-08 · $22
GenzymeLibtayo$7,353
2 payments
  • Consulting for Libtayo · 2022-12-12 · $5,190
  • Consulting for Sarclisa · 2022-03-25 · $2,163
Takeda Pharmaceuticals U.S.A.Exkivity$6,750
2 payments
  • Consulting for Exkivity · 2022-12-01 · $4,950
  • Consulting · 2022-02-18 · $1,800
Gilead SciencesNone$2,570
1 payment
  • Consulting · 2022-06-28 · $2,570
Genentech USATecentriq$2,200
1 payment
  • Consulting for Tecentriq · 2022-04-21 · $2,200
Janssen Scientific AffairsRybrevant$2,170
1 payment
  • Consulting for Rybrevant · 2022-05-12 · $2,170
Regeneron Healthcare SolutionsLibtayo$1,965
1 payment
  • Consulting for Libtayo · 2022-01-21 · $1,965
ExelixisCabometyx$157
1 payment
  • Meals for Cabometyx · 2022-06-04 · $157
AstraZeneca Pharmaceuticals LPTagrisso$123
1 payment
  • Meals for Tagrisso · 2022-11-11 · $123
Jazz PharmaceuticalsZepzelca$30
1 payment
  • Meals for Zepzelca · 2022-06-04 · $30

2021: $23,084

Payments by company in 2021
Takeda Pharmaceuticals U.S.A.Exkivity$9,540
3 payments
  • Consulting for Exkivity · 2021-10-23 · $6,075
  • Consulting for Exkivity · 2021-02-26 · $1,733
  • Consulting for Exkivity · 2021-02-26 · $1,733
Regeneron PharmaceuticalsLibtayo$3,635
2 payments
  • Consulting for Libtayo · 2021-12-23 · $1,310
  • Consulting for Libtayo · 2021-12-23 · $2,325
Regeneron Healthcare SolutionsLibtayo$2,620
1 payment
  • Consulting for Libtayo · 2021-01-15 · $2,620
GenzymeLibtayo$2,289
1 payment
  • Consulting for Libtayo · 2021-11-15 · $2,289
AmgenNplate$2,200
1 payment
  • Consulting for Nplate · 2021-08-16 · $2,200
Blueprint MedicinesNone$1,400
1 payment
  • Honoraria · 2021-07-02 · $1,400
Eli Lilly andNone$1,400
1 payment
  • Consulting · 2021-05-19 · $1,400

2020: $11,174

Payments by company in 2020
Eli Lilly andNone$7,700
1 payment
  • Consulting · 2020-10-22 · $7,700
AmgenNplate$1,930
1 payment
  • Consulting for Nplate · 2020-05-28 · $1,930
Blueprint MedicinesNone$1,544
1 payment
  • Honoraria · 2020-09-09 · $1,544

2019: $4,115

Payments by company in 2019
Genentech USAAlecensa$4,029
5 payments
  • Meals for Avastin · 2019-06-01 · $127
  • Meals for Alecensa · 2019-02-20 · $155
  • Meals for Alecensa · 2019-02-20 · $199
  • Travel for Alecensa · 2019-02-20 · $448
  • Consulting for Alecensa · 2019-02-20 · $3,100
Novartis PharmaceuticalsInc280$87
1 payment
  • Meals for Inc280 · 2019-10-10 · $87

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Janssen Research & Development, LLC · A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced Or Metastatic Solid Tumors Including Egfr-Mutated Non-Small Cell Lung Cancer. · 2025Their institution$1,130,135
Merck Sharp & Dohme Corporation · Phase II Trial of Pembrolizumab in Metastatic Non-Squamous Nsclc Examining Circulating Tumor Dna Levels As A Surrogate Biomarker of Response · 2020Their institution$494,484
AstraZeneca Pharmaceuticals LP · Adjuvant Durvalumab for Early Stage Non-Small Cell Lung Cancer Patients With Ctdna Minimal Residual Disease · 2022Their institution$400,705
Janssen Research & Development, LLC · An Open Label Phase 11b Study To Evaluate the Safety and Pharmacokinetics of Jnj73841937 Lazertinib A Third Generation Egfrtki As Monotherapy Or in Combinations With Jnj61186372 A Human Bispecific Egfr and Cmet Antibody in Participants With Advanced Non Small Cell Lung Cancer · 2023Their institution$392,166
Merck Sharp & Dohme Corporation · Phase II Trial of Pembrolizumab in Metastatic Non-Squamous Nsclc Examining Circulating Tumor Dna Levels As A Surrogate Biomarker of Response · 2019Their institution$353,981
Janssen Research & Development, LLC · An Open Label Phase 11b Study To Evaluate the Safety and Pharmacokinetics of Jnj73841937 Lazertinib A Third Generation Egfrtki As Monotherapy Or in Combinations With Jnj61186372 A Human Bispecific Egfr and Cmet Antibody in Participants With Advanced Non Sm · 2021Their institution$327,699
Janssen Research & Development, LLC · An Open Label Phase 11b Study To Evaluate the Safety and Pharmacokinetics of Jnj73841937 Lazertinib A Third Generation Egfrtki As Monotherapy Or in Combinations With Jnj61186372 A Human Bispecific Egfr and Cmet Antibody in Participants With Advanced Non Small Cell Lung Cancer · 2022Their institution$325,105
Merck Sharp & Dohme Corporation · Phase II Trial of Pembrolizumab in Metastatic Non-Squamous Nsclc Examining Circulating Tumor Dna Levels As A Surrogate Biomarker of Response · 2021Their institution$294,259
Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2023Their institution$241,824
Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2022Their institution$235,370
AstraZeneca Pharmaceuticals LP · Adjuvant Durvalumab for Early Stage Non-Small Cell Lung Cancer Patients With Ctdna Minimal Residual Disease · 2023Their institution$211,630
Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral Egfr/Her2 Inhibitor Tak-788 (Ap32788) in Non-Small Cell Lung Cancer · 2020Their institution$200,617
AstraZeneca Pharmaceuticals LP · Adjuvant Durvalumab for Early Stage Non-Small Cell Lung Cancer Patients With Ctdna Minimal Residual Disease · 2021Their institution$197,479
E.R. Squibb & Sons, L.L.C. · A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous Nsclc · 2023Their institution$141,504
AstraZeneca Pharmaceuticals LP · Adjuvant Durvalumab for Early Stage Non-Small Cell Lung Cancer Patients With Ctdna Minimal Residual Disease · 2024Their institution$123,837
Janssen Research & Development, LLC · An Open Label Phase 11b Study To Evaluate the Safety and Pharmacokinetics of Jnj73841937 Lazertinib A Third Generation Egfrtki As Monotherapy Or in Combinations With Jnj61186372 A Human Bispecific Egfr and Cmet Antibody in Participants With Advanced Non Small Cell Lung Cancer · 2024Their institution$117,737
Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2025Their institution$114,942
Exelixis Inc. · Xl184-Ctep-E1512 · 2022Their institution$104,000
GlaxoSmithKline, LLC. · A Phase 1b/2a Pilot Study To Evaluate the Safety and Tolerability of A · 2021Their institution$85,046
Janssen Research & Development, LLC · A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced Or Metastatic Solid Tumors Including Egfr-Mutated Non-Small Cell Lung Cancer. · 2024Their institution$79,381
E.R. Squibb & Sons, L.L.C. · A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous Nsclc · 2024Their institution$64,856
Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral Egfr/Her2 Inhibitor Tak-788 (Ap32788) in Non-Small Cell Lung Cancer · 2024Their institution$52,918
GlaxoSmithKline, LLC. · A Phase 1b/2a Pilot Study To Evaluate the Safety and Tolerability of A · 2022Their institution$52,369
Janssen Research & Development, LLC · An Open Label Phase 11b Study To Evaluate the Safety and Pharmacokinetics of Jnj73841937 Lazertinib A Third Generation Egfrtki As Monotherapy Or in Combinations With Jnj61186372 A Human Bispecific Egfr and Cmet Antibody in Participants With Advanced Non Small Cell Lung Cancer · 2025Their institution$51,025
GlaxoSmithKline, LLC. · A Phase 1b/2a Pilot Study To Evaluate the Safety and Tolerability of A · 2020Their institution$50,352
Exelixis Inc. · A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous Nsclc · 2024Their institution$47,667
Merck Sharp & Dohme LLC · Phase II Trial of Pembrolizumab in Metastatic Non-Squamous Nsclc Examining Circulating Tumor Dna Levels As A Surrogate Biomarker of Response · 2024Their institution$35,194
Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral Egfr/Her2 Inhibitor Tak-788 (Ap32788) in Non-Small Cell Lung Cancer · 2021Their institution$33,078
Janssen Research & Development, LLC · A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced Or Metastatic Solid Tumors Including Egfr-Mutated Non-Small Cell Lung Cancer. · 2023Their institution$31,354
ABBVIE INC. · An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With Ptk7-Expressing, Recurrent Non-Small Cell Lung Cancer · 2022Their institution$30,733
Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2021Their institution$28,213
Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2024Their institution$25,641
AstraZeneca UK Limited · Tagrisso Testing Tx Patterns Rwo Early Stage Nsclc · 2024Their institution$20,400
Genentech, Inc. · Atezolizumab Cabozantinib Vs Docetaxel in Metastatic Nsclc Previously Treated With Cpi Chemo · 2024Their institution$12,745
GlaxoSmithKline, LLC. · A Phase 1b/2a Pilot Study To Evaluate the Safety and Tolerability of A · 2024Their institution$11,985
AstraZeneca UK Limited · Tagrisso Testing Tx Patterns Rwo Early Stage Nsclc · 2023Their institution$10,010
Merck Sharp & Dohme LLC · Phase II Trial of Pembrolizumab in Metastatic Non-Squamous Nsclc Examining Circulating Tumor Dna Levels As A Surrogate Biomarker of Response · 2023Their institution$5,279
Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral Egfr/Her2 Inhibitor Tak-788 (Ap32788) in Non-Small Cell Lung Cancer · 2022Their institution$4,377
GlaxoSmithKline, LLC. · A Phase 1b/2a Pilot Study To Evaluate the Safety and Tolerability of A · 2023Their institution$2,776
Takeda Pharmaceuticals U.S.A., Inc. · A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral Egfr/Her2 Inhibitor Tak-788 (Ap32788) in Non-Small Cell Lung Cancer · 2023Their institution$2,703
ABBVIE INC. · A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (Abbv-647, A Ptk7-Targeting Antibody Drug Conjugate) in Subjects With Ptk7-Expressing, Recurrent Non-Small Cell Lung Cancer · 2021Their institution$773
F. Hoffmann-La Roche AG · Atezolizumab Cabozantinib Vs Docetaxel in Metastatic Nsclc Previously Treated With Cpi Chemo · 2023This clinician$638
ViiV Healthcare Company · A Phase 1b/2a Pilot Study To Evaluate the Safety and Tolerability of A · 2022Their institution$576
Eli Lilly and Company · A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected Or Unresectable Kras G12c-Mutant, Non-Small Cell Lung Cancer - Sunray-02 · 2025Their institution$478
Novartis Pharmaceuticals Corporation · A Phase II Multi Center Open Label Single Arm Study To Evaluate the Efficacy and Safety of Oral Ldk378 Treatment for Patients With Alk Rearranged Non Small Cell Lung Cancer Metastatic To the Brain · 2021Their institution$230
Novartis Pharmaceuticals Corporation · A Phase III Randomized Study of Canakinumab + Pembrolizumab Alone As Maintenace Therapy Following Chemotherapy + Pembrolizumab Induction Therapy in Previously Untreated Adult Patients With Stage Iiib Or IV Non-Small Cell Lung Cancer. · 2019Their institution$181
Merck Sharp & Dohme LLC · A Phase II,III Randomized Trial of Two Doses of Mk-3475 Sch 900475 Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer · 2022Their institution$91
Novartis Pharmaceuticals Corporation · A Phase III Randomized Study of Canakinumab + Pembrolizumab Alone As Maintenace Therapy Following Chemotherapy + Pembrolizumab Induction Therapy in Previously Untreated Adult Patients With Stage Iiib Or IV Non-Small Cell Lung Cancer. · 2020Their institution$65

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1790858942
Licence
CA A111199, MA 230363California A111199: Current · expires 2027-08-31
Trained
Northwestern University Feinberg Medical School, 2004
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2006-11-16
NPI last updated
2024-04-15
NPI record certified
2024-04-15

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 875 Blake Wilbur Dr, Stanford, CA, 94305